Sanofi-Aventis Expands R&D Presence In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Sanofi-Aventis recently expanded its R&D presence in China to meet the rapid growth of clinical programs and broaden its activities from drug-target identification to late-stage clinical studies
You may also be interested in...
Sanofi-Aventis China R&D Head Jiang On Fast And Furious Adaptation In China
Sanofi-Aventis is grabbing a larger share of the emerging markets from many of its rivals, such as Pfizer and Wyeth, Novartis, GlaxoSmithKline and Merck and Schering-Plough. Part of the reason behind Sanofi's success is its aggressive strategy in China, where it currently has 3,500 employees in vaccines, R&D, commercial operations and manufacturing. Sanofi-Aventis China R&D Head Frank Jiang sat down for a recent interview to discuss the environment in China and how Sanofi is approaching R&D there.
Sanofi-Aventis China R&D Head Jiang On Fast And Furious Adaptation In China
Sanofi-Aventis is grabbing a larger share of the emerging markets from many of its rivals, such as Pfizer and Wyeth, Novartis, GlaxoSmithKline and Merck and Schering-Plough. Part of the reason behind Sanofi's success is its aggressive strategy in China, where it currently has 3,500 employees in vaccines, R&D, commercial operations and manufacturing. Sanofi-Aventis China R&D Head Frank Jiang sat down for a recent interview to discuss the environment in China and how Sanofi is approaching R&D there.
Sanofi-Aventis China R&D Head Frank Jiang On Fast And Furious Adaptation In China: An Interview With PharmAsia News (Part 2 of 2)
Sanofi-Aventis is grabbing a larger share of emerging markets from many of its rivals, such as Pfizer and Wyeth, Novartis, GlaxoSmithKline and Merck and Schering Plough. Part of the reason behind Sanofi's success is its aggressive strategy in China, where it currently has 3,500 employees in vaccines, R&D, commercial operations and manufacturing. Sanofi-Aventis China R&D Head Frank Jiang sat down with PharmAsia News to discuss the environment in China and how Sanofi is approaching R&D there. Jiang is also a member of the networking organization BayHelix, which links Chinese life sciences executives.